- Home
- TNON vs RNAZ Comparison
TNON vs RNAZ Comparison
Compare TNON & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNON | RNAZ |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | 26 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 8.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TNON | RNAZ |
|---|---|---|
| Price | $0.20 | $8.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.4M | 26.9K |
| Earning Date | 05-05-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $65.95 | N/A |
| Revenue Next Year | $50.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $3.82 |
| 52 Week High | $2.48 | $20.99 |
Technical Indicators
Market Signals| Indicator | TNON | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 26.48 | 58.09 |
| Support Level | $0.19 | $8.38 |
| Resistance Level | $0.81 | $9.93 |
| Average True Range (ATR) | 0.02 | 1.19 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 4.12 | 49.56 |
Price Performance
Historical ComparisonAbout TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.